Psychedelic MedicineAssociation

Getting Paid for Psychedelic Medicine: The Billing Codes, the Payor Rules, and the Road Ahead

Monday, August 17, 2026

Getting Paid for Psychedelic Medicine: The Billing Codes, the Payor Rules, and the Road Ahead

Host

Lynn Marie Morski, MD, JD

Lynn Marie Morski, MD, JD

President, Psychedelic Medicine Association

About This Webinar

FDA approval has never guaranteed patient access, and for psychedelic therapeutics, the gap between regulatory success and reimbursement reality could be wider than for any therapy class that has come before.

With the Compass Pathways psilocybin NDA on track for Q4 2026, the field has a finite window – roughly 12 to 18 months – to build the billing and coverage infrastructure that Spravato®'s developers did not have when esketamine was approved in 2019. The result of that failure is still visible: inconsistent commercial coverage, unresolved Medicare classification, and billing complexity that many practices navigate imperfectly today, despite the drug approaching blockbuster sales.

The session is for everyone who needs to understand that billing strategy and payor engagement are not post-approval problems. They are pre-approval requirements – and the window to act is open right now.

This session provides a practical, compliance-grounded roadmap for closing that gap before the first psychedelic NDA arrives. Attorney Kimberly Chew, Co-Leader of Husch Blackwell's Psychedelics & Emerging Therapies Practice, will walk through:

  • The three Category III CPT codes created specifically for psychedelic-assisted therapy – 0820T, 0821T, and 0822T – what they cover, what they do not, and how every claim filed under them today contributes to the dataset that supports future Category I conversion.
  • FDA's June 2026 draft guidance on pre-approval payor communications, including what developers, clinical investigators, and institutions are now permitted to share with insurers under the section 502(gg) safe harbor and the compliance obligations that come with it.

As always, there will be ample time for audience Q & A, so you’ll get to interact with the panelists directly!

So please join us for this live panel discussion on August 25th at 5 pm Pacific, 8 pm Eastern. A link to the recording will be available afterward if you cannot make it to the live event.

Hope to see you all on the 25th!

Panelists

Kimberly Chew, Esq.Kimberly Chew, Esq. – Senior Counsel, Husch Blackwell; Co-Founder & Co-Lead, Psychedelic and Emerging Therapies Practice Group

Kimberly Chew, Esq. is senior counsel at Husch Blackwell LLP , where she co-leads the firm’s Psychedelic and Emerging Therapies practice group . Kimberly guides clients through complex regulatory and commercialization challenges in the life sciences sector, with a focus on drug and device development, FDA and DEA compliance, and the rapidly evolving legal landscape for psychedelic and emerging therapies. Before practicing law, Kimberly spent 16 years as a research scientist. This dual background enables her to combine legal knowledge with scientific insight, providing holistic and practical solutions to clients at the forefront of innovation.

Joseph MooreJoseph Moore – CEO & Co-founder, Psychedelics Today

Joe Moore is the co-founder and CEO of Psychedelics Today , a leading media and education platform exploring the science and culture of psychedelics. Since 2016, he’s hosted hundreds of interviews with researchers, clinicians, and visionaries shaping the psychedelic renaissance. Joe also co-created Vital , a year-long training for practitioners, and teaches at the intersection of breathwork, philosophy, and integration. He lives in Colorado, where he leads Transpersonal Breathwork workshops and continues building psychedelic education worldwide.

Kayli Howard, MAKayli Howard, MA – Licensed Psilocybin Facilitator, Marriage & Family Therapist Associate, Trainer Faculty for Fluence

Kayli Howard has a MA in Clinical Psychology from Antioch University, where she trained as a Marriage and Family Therapist. In 2023 she received certification in Psilocybin-Assisted Therapy through Fluence. She is one of Oregon’s first licensed psilocybin facilitators. Since receiving licensure she has guided nearly 150 legal psychedelic journeys and was awarded the "Clients' Choice" in Althea's Psilocybin Outcome Awards. She trains upcoming psychedelic facilitators as a faculty member of Fluence’s Colorado Natural Medicine program.

Reid Robison, MD, MBAReid Robison, MD, MBA – Chief Medical Officer at Novamind/Co-founder at Cedar Psychiatry

Dr. Reid Robison is a board-certified psychiatrist and Chief Medical Officer at Novamind. Reid is co-founder at Cedar Psychiatry and serves as Medical Director of Center for Change, a top Eating Disorder program. He is currently the coordinating investigator for the MAPS MDMA-assisted Psychotherapy study of Eating Disorders. Reid is adjunct faculty at the University of Utah, founder of the Polizzi Free Clinic, and provides medical support and psychedelic therapy at plant medicine retreats abroad.

Exclusive for members

Recordings and live registration are available after you sign in as a PMA member.

Sign in